An interventional study of chosen TAVI valve in Transcatheter Aortic Valve Implantation, sponsored by Aarhus University Hospital Skejby. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Aarhus University Hospital Skejby · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study performs head-to-head comparison of two TAVI-valves: Sapien and Myval.
The purpose of the present study is to ensure a continuous comparison of the TAVI-valves implanted, and to monitor long-term valve performances.
Purpose: To randomize between two TAVI-valve types in patients who according to a heart team conference is found eligible for treatment with more than one valve.
Hypotheses:
Design: Randomized controlled trial with clinical national registry follow-up.
Centers eligible for inclusion: Scandinavian and European centers who fulfill the above mentioned criteria.
Randomization:
Before randomizing patients, the center decides which two valves the patient is found eligible for, and enters these valves in the electronic randomization form (TrialPartner). Randomization is then performed between these two valves. A patient is only randomized if a dedicated technical TAVI conference has found the patient eligible for treatment with both valves.
Consecutive cohorts are established.
In the current study we plan to initiate the following cohorts:
Cohort B: Patients randomized to the Sapien or the Myval TAVI valve.
Operator requirements:
Any procedure requires that the physician has performed at least 15 implantations with the valve in use. Otherwise the procedure is performed according to the routine of the institution.
Aarhus University Hospital Skejby is the lead sponsor of 60 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Not able to give written inform consent
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to treatment
Device: chosen TAVI valve
Patients randomized to treatment
Device: chosen TAVI valve
chosen TAVI valve
Percentage of patients with MACE (Major Adverse Cardiovascular Events)
Mortality, stroke, moderate/major PVL, moderate/severe aortic device stenosis at 1 year, using VARC-3 criteria
Time frame: 1 year
Percentage of patients with MACE
Mortality, stroke, moderate/major paravalvular leakage (PVL), moderate/severe aortic device stenosis at 1 year, using VARC-3 criteria
Time frame: 30 day, 3-year, 5-year and 10-year
Percentage death
Mortality
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with stroke
According to Valve Academic Research Consortium (VARC)-3 criteria
Time frame: During admission, 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with moderate or severe paravalvular leakage
Moderate or severe paravalvular leakage according to VARC-3 criteria
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with moderate/major aortic stenosis
According to VARC-3 criteria
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with new pacemaker
New Pacemaker after TAVI-procedure
Time frame: During admission, 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with major bleeding
Major bleeding according to Bleeding Academic Research Consortium (BARC) type 3 or 5 criteria, resulting in either a drop in Hbg\>=1.86 mmol/l or \>=2 units of blood transfusion
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Distance in meters during 6-minute walk test
6-minute walk test
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with other TAVI-related complications
conversion to open surgery during implantation, unplanned use of cardiopulmonary support (CPS), coronary artery obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, valve thrombosis, valve embolization, valve migration, need for TAVI-in-TAVI deployment, using VARC-3 criteria
Time frame: During TAVI-procedure
Percentage of patients with endocarditis
Endocarditis
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Proportion with successful implantation of the chosen valve.
This means no need for more than 1 TAVI valve, no change to another valve than planned during the procedure because it was impossible to implant the valve planned, and no conversion to surgery or procedure-related death.
Time frame: During procedure
Percentage of patients with major vascular access site and access-related complications
According to VARC-3 criteria
Time frame: During admission and 30-day
Percentage of patients with valve thrombosis or severe stenosis
Valve thrombosis or severe stenosis confirmed by Echo or HCT
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with readmission with congestive heart failure
Readmission with congestive heart failure
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Percentage of patients with increase in creatinin level of 100% or more, or dialysis
Increase in renal creatinine level more than to \>=200% (AKIN stage 2-3, VARC-3 criteria) or dialysis
Time frame: during admission and within 30 days
Percentage of patients with moderate/severe PVL stratified according to level of annular calcium on HCT in three groups
Severity of PVL stratified according to level of annular calcium on HCT (low/medium/high)
Time frame: 30-day
Mean Gradient (AO) stratified according to level of annular calcium on HCT in three groups
Gradient (AO) stratified according to level of annular calcium on HCT (low/medium/high)
Time frame: 30-day
Percentage of patients with prosthesis-patient mismatch
Prosthesis-patient mismatch (EOA/body surface area). Severe PPM≤0.65 cm2/m2. Moderate PPM≤0.85 cm2/m2 according to VARC-3 criteria
Time frame: 30-day, 1-year, 3-year, 5-year, 10-year
Mean effective orifice area measured by MRI
Effective orifice area measured by MRI in patients participating in MRI-substudy
Time frame: 30-day
Percentage of patients with leaflet thickening (hypoattenuated leaflet thickening = HALT) or reduced leaflet motion or thrombus assessed by HCT
Leaflet thickening (hypoattenuated leaflet thickening = HALT) or reduced leaflet motion or thrombus assessed by HCT in patients participating in HCT-substudy
Time frame: 30-day and 1-year
Mean volume of aortic regurgitation measured by MRI
Volume of aortic regurgitation measured by MRI in patients participating in MRI-substudy
Time frame: 30-day
Other tavi-related complications
Anulus rupture or aortic rupture
Time frame: 30-day
AMI
Acute Myocardial Infarction
Time frame: 30-day, 1-year, 3-year, 5-year and 10-year
PCI og CABG
Percutaneous Coronary Intervention or coronary artery bypass grafting
Time frame: 30-day, 1-year, 3-year, 5-year and 10-year
Reopeation
Reopeation with TAVI, Surgical ortic valve replacement (SAVR) or BAV (Balloon aortic valvuloplasty) according to VARC-3 criteria
Time frame: 30-day, 1-year, 3-year, 5-year and 10-year
Afib
Newly diagnosed atrial fibrillation according to VARC-3 criteria
Time frame: 30-day, 1-year, 3-year, 5-year and 10-year.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Normally this will be possible when data are published and anonymized. Mainly to support meta-analysis on individual level data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When endpoints are published in an international peer-reviewed paper
Access criteria: To share data there shall be a well-defined purpose. This could be to contribute to a meta-analysis on individual level data.
Ran from Jun 2020 to primary completion in Nov 2023, 40 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital Skejby